已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Once-daily, single-inhaler mometasone–indacaterol–glycopyrronium versus mometasone–indacaterol or twice-daily fluticasone–salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study

茚达特罗 医学 糠酸莫米松 哮喘 吸入器 皮质类固醇 沙美特罗 内科学 麻醉 氟替卡松 支气管扩张剂
作者
Huib A.M. Kerstjens,Jorge Máspero,Kenneth R. Chapman,Richard N. van Zyl-Smit,Motoi Hosoe,Ana-Maria Tanase,Catherine Lavecchia,Abhijit Pethe,Xu Shu,Peter D’Andrea
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:8 (10): 1000-1012 被引量:159
标识
DOI:10.1016/s2213-2600(20)30190-9
摘要

Patients with asthma who are inadequately controlled on inhaled corticosteroid-long-acting β2-adrenoceptor agonist (ICS-LABA) combinations might benefit from the addition of a long-acting muscarinic receptor antagonist. The aim of the IRIDIUM study was to assess the efficacy and safety of a once-daily, single-inhaler combination of mometasone furoate, indacaterol acetate, and glycopyrronium bromide (MF-IND-GLY) versus ICS-LABA in patients with inadequately controlled asthma.In this 52-week, double-blind, double-dummy, parallel-group, active-controlled phase 3 study, patients were recruited from 415 sites across 41 countries. Patients aged 18 to 75 years with symptomatic asthma despite treatment with medium-dose or high-dose ICS-LABA, at least one exacerbation in the previous year, and a percentage of predicted FEV1 of less than 80% were included. Enrolled patients were randomly assigned (1:1:1:1:1) via interactive response technology to receive medium-dose or high-dose MF-IND-GLY (80 μg, 150 μg, 50 μg; 160 μg, 150 μg, 50 μg) or MF-IND (160 μg, 150 μg; 320 μg, 150 μg) once daily via Breezhaler, or high-dose fluticasone-salmeterol (FLU-SAL; 500 μg, 50 μg) twice daily via Diskus. The primary outcome was change from baseline in trough FEV1 with MF-IND-GLY versus MF-IND at week 26 in patients in the full analysis set, analysed by means of a mixed model for repeated measures. Safety was assessed in all patients who received at least one dose of study drug. This study is registered with ClinicalTrials.gov, NCT02571777, and is completed.Between Dec 8, 2015, and Jun 14, 2019, 3092 of 4851 patients screened were randomly assigned (medium-dose MF-IND-GLY, n=620; high-dose MF-IND-GLY, n=619; medium-dose MF-IND, n=617; high-dose MF-IND, n=618; high-dose FLU-SAL, n=618). 2747 (88·8%) patients completed the 52-week treatment and 321 (10·4%) started but discontinued study treatment prematurely. Medium-dose MF-IND-GLY (treatment difference [Δ] 76 mL [95% CI 41-111]; p<0·001) and high-dose MF-IND-GLY (Δ 65 mL [31-99]; p<0·001) showed superior improvement in trough FEV1 versus corresponding doses of MF-IND at week 26. Improvements in trough FEV1 were greater for both medium-dose MF-IND-GLY (99 mL [64-133]; p<0·001) and high-dose MF-IND-GLY (119 mL [85-154]; p<0·001) than for high-dose FLU-SAL at week 26. Overall, the incidence of adverse events was balanced across the treatment groups. Seven deaths were reported (one with medium-dose MF-IND-GLY, two with high-dose MF-IND-GLY, and four with high-dose MF-IND) during the study; none of these deaths was considered by the investigators to be caused by study drugs or other study-related factors.Once-daily, single-inhaler MF-IND-GLY improved lung function versus ICS-LABA combinations (MF-IND and FLU-SAL) in patients with inadequately controlled asthma. The safety profile was similar across treatment groups. MF-IND-GLY therefore constitutes a good treatment option in these patients.Novartis Pharmaceuticals.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
fbjbzj完成签到,获得积分10
刚刚
M1发布了新的文献求助10
1秒前
伶俐初蓝完成签到 ,获得积分10
1秒前
一点浩然气完成签到 ,获得积分10
3秒前
4秒前
研友_VZG7GZ的应助被zhang采纳,获得10
5秒前
6秒前
向未来完成签到,获得积分10
6秒前
威武的凡双完成签到,获得积分10
7秒前
所所的应助被无心的思松采纳,获得10
7秒前
8秒前
8秒前
FashionBoy的应助被liurong采纳,获得10
9秒前
9秒前
甜甜玉米完成签到 ,获得积分10
9秒前
10秒前
10秒前
Hello的应助被u511277采纳,获得10
11秒前
贾茜茜完成签到 ,获得积分10
11秒前
老莫发布了新的文献求助10
11秒前
巧巧发布了新的文献求助10
12秒前
13秒前
14秒前
lililili发布了新的文献求助10
14秒前
cc发布了新的文献求助10
16秒前
wan的应助被耍酷大山采纳,获得10
16秒前
gyq发布了新的文献求助10
16秒前
传奇3的应助被耍酷大山采纳,获得10
16秒前
科研通AI65的应助被耍酷大山采纳,获得10
16秒前
科研通AI6.4的应助被耍酷大山采纳,获得10
16秒前
sw123完成签到 ,获得积分10
16秒前
科研通AI6.2的应助被耍酷大山采纳,获得10
16秒前
科研通AI6.3的应助被耍酷大山采纳,获得10
17秒前
星辰大海的应助被耍酷大山采纳,获得10
17秒前
Maestro_S的应助被耍酷大山采纳,获得10
17秒前
Maestro_S的应助被耍酷大山采纳,获得10
17秒前
17秒前
18秒前
喜哦肖完成签到,获得积分10
19秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8194612
求助须知:如何正确求助?哪些是违规求助? 9580394
关于积分的说明 21870930
捐赠科研通 7794182
什么是DOI,文献DOI怎么找? 3437711
关于科研通互助平台的介绍 2561001
邀请新用户注册赠送积分活动 2484411